Top Industry Leaders in the Alpha Thalassemia Market
Latest Alpha Thalassemia Companies Updates:
Agios Pharmaceuticals: Their lead candidate, AGIO977, for Beta-thalassemia is facing challenges in late-stage trials, impacting their alpha-thalassemia development plans. (Source: Seeking Alpha)
Forma Therapeutics: Their experimental gene therapy, FT011, for beta-thalassemia is showing promising results in early-stage trials, potentially extending to alpha-thalassemia treatment in the future. (Source: Forma Therapeutics website)
Silence Therapeutics: This biotech company is developing SIRNA-based gene silencing therapies for both alpha and beta-thalassemia, with promising preclinical data. (Source: Silence Therapeutics website)
Other players: Companies like CRISPR Therapeutics, DisperSol Technologies, and Celgene are also actively involved in research and development for alpha-thalassemia treatments.
List of Alpha Thalassemia Key companies in the market:
- Alnylam Pharmaceuticals Inc
- Calimmune Inc
- CRISPR Therapeutics
- Editas Medicine Inc
- Errant Gene Therapeutics LLC
- Gamida Cell Ltd
- Gilead Sciences Inc
- Incyte Corp
- Ionis Pharmaceuticals Inc
- IRBM Science Park SpA
- Johnson & Johnson
- Kiadis Pharma NV
- La Jolla Pharmaceutical Company
- Merck & Co Inc
- PharmaEssentia Corp
- Protagonist Therapeutics Inc